Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QGEN 
Qiagen NV (QGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: QGEN (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $51.64
1 Year Target Price $51.64
| 6 | Strong Buy |
| 3 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.45% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.47B USD | Price to earnings Ratio 28.56 | 1Y Target Price 51.64 |
Price to earnings Ratio 28.56 | 1Y Target Price 51.64 | ||
Volume (30-day avg) 16 | Beta 0.66 | 52 Weeks Range 37.43 - 51.88 | Updated Date 10/19/2025 |
52 Weeks Range 37.43 - 51.88 | Updated Date 10/19/2025 | ||
Dividends yield (FY) 0.52% | Basic EPS (TTM) 1.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 18.3% | Operating Margin (TTM) 25.49% |
Management Effectiveness
Return on Assets (TTM) 9.01% | Return on Equity (TTM) 10.81% |
Valuation
Trailing PE 28.56 | Forward PE 16.95 | Enterprise Value 10516637598 | Price to Sales(TTM) 5.13 |
Enterprise Value 10516637598 | Price to Sales(TTM) 5.13 | ||
Enterprise Value to Revenue 5.16 | Enterprise Value to EBITDA 14.71 | Shares Outstanding 216834269 | Shares Floating 214891167 |
Shares Outstanding 216834269 | Shares Floating 214891167 | ||
Percent Insiders 1.61 | Percent Institutions 79.62 |
Upturn AI SWOT
Qiagen NV
Company Overview
History and Background
Qiagen NV was founded in 1984 in Dusseldorf, Germany. Initially focused on RNA and DNA purification, it has grown through internal development and acquisitions to become a leading provider of sample preparation and molecular testing solutions.
Core Business Areas
- Sample Technologies: Provides solutions for extracting, isolating, and purifying DNA, RNA, and proteins from biological samples. This includes kits, reagents, and automated platforms.
- Molecular Diagnostics: Develops and commercializes molecular diagnostic tests for various applications, including infectious diseases, oncology, and inherited conditions. This includes real-time PCR, next-generation sequencing (NGS), and companion diagnostics.
- Life Science Research: Offers a range of tools and technologies for life science research, including genomics, proteomics, and cell biology. This includes instruments, reagents, and software.
Leadership and Structure
Qiagen NV is led by Thierry Bernard (CEO). The company operates with a global organizational structure, with key functions including Research & Development, Manufacturing, Sales & Marketing, and Finance.
Top Products and Market Share
Key Offerings
- QIAamp Kits: A leading line of sample preparation kits for DNA and RNA extraction. Competitors include Thermo Fisher Scientific, Roche, and Bio-Rad. Market data hard to acquire
- QuantiFERON-TB Gold Plus: A blood test for detecting latent tuberculosis infection. Competitors include Oxford Immunotec. Market data hard to acquire
- NeuMoDx Molecular Systems: Automated molecular testing platforms for clinical diagnostics. Competitors include Roche, Abbott, and Hologic. Market data hard to acquire
Market Dynamics
Industry Overview
The molecular diagnostics and life sciences tools industries are experiencing strong growth, driven by advances in genomics, proteomics, and personalized medicine. Key trends include increasing automation, point-of-care testing, and the development of novel biomarkers.
Positioning
Qiagen NV holds a strong position in the sample preparation and molecular diagnostics markets, with a reputation for quality and innovation. Its competitive advantages include a broad product portfolio, strong brand recognition, and a global sales and service network.
Total Addressable Market (TAM)
The molecular diagnostics market is expected to reach hundreds of billions of dollars within the next few years. Qiagen is positioned to capture a significant portion of this market through continued innovation and expansion of its product offerings.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Broad product portfolio
- Global sales and service network
- Innovative technology platform
- Expertise in sample preparation
Weaknesses
- Competition from larger players
- Dependency on research and development
- Exposure to regulatory risks
- Price erosion in certain markets
Opportunities
- Expansion into emerging markets
- Development of new diagnostic tests
- Growth in personalized medicine
- Strategic acquisitions and partnerships
- Increasing demand for automation
Threats
- Increased competition
- Technological obsolescence
- Economic downturn
- Changes in healthcare regulations
- Disruptive technologies
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Roche Holding AG (RHHBY)
- Danaher Corporation (DHR)
- Agilent Technologies (A)
Competitive Landscape
Qiagen NV faces competition from larger, more diversified companies, but it maintains a competitive edge through its focus on sample preparation and molecular diagnostics.
Major Acquisitions
Exiqon A/S
- Year: 2016
- Acquisition Price (USD millions): 160
- Strategic Rationale: Enhanced Qiagen NV's capabilities in microRNA research and diagnostics.
Growth Trajectory and Initiatives
Historical Growth: Qiagen NV has experienced consistent growth in revenue and earnings over the past decade, driven by strong demand for its products and services.
Future Projections: Analyst estimates project continued growth for Qiagen NV, driven by its strong market position and innovative product pipeline.
Recent Initiatives: Recent strategic initiatives include acquisitions of companies to expand product offerings and geographic reach.
Summary
Qiagen NV is a strong player in the sample preparation and molecular diagnostics markets with a broad product portfolio and global reach. It faces competition from larger companies but has a solid foundation for future growth through innovation and strategic initiatives. The company needs to stay ahead of technological advancements and effectively manage regulatory risks. Overall the company seems like it can be a strong long term investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided may not be exhaustive, and financial figures are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Qiagen NV
Exchange NYSE | Headquaters - | ||
IPO Launch date 1996-06-28 | CEO, MD & Member of Management Board Mr. Thierry Bernard | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 5700 | Website https://www.qiagen.com |
Full time employees 5700 | Website https://www.qiagen.com | ||
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.